Therapy of murine squamous cell carcinomas with 2-difluoromethylornithine
Yan Chen1, Juncai Hu1, David Boorman1, Andres Klein-Szanto2, Thomas G O'Brien1
1 Lankenau Institute for Medical Research 100 Lancaster Avenue, Wynnewood, PA 19096, USA
2 Fox Chase Cancer Center 7701 Burholme Avenue Philadelphia, PA 19111, USA
|Date of Submission||28-Jan-2004|
|Date of Acceptance||02-Jun-2004|
|Date of Web Publication||02-Jun-2004|
Thomas G O'Brien
Lankenau Institute for Medical Research 100 Lancaster Avenue, Wynnewood, PA 19096
Source of Support: None, Conflict of Interest: None
Targeted overexpression of an ornithine decarboxylase (ODC) transgene to mouse skin (the K6/ODC mouse) significantly enhances susceptibility to carcinogenesis. While in most strain backgrounds the predominant tumor type resulting from initiation-promotion protocols is benign squamous papilloma, K6/ODC mice on a FVB/N background develop malignant squamous cell carcinomas (SCCs) rapidly and in high multiplicity after carcinogen treatment. We have investigated the utility of polyamine-based therapy against SCCs in this model using the ODC inhibitor 2-difluoromethylornithine delivered orally. At a 2% concentration in drinking water, DFMO caused rapid tumor regression, but in most cases, tumors eventually regrew rapidly even in the presence of DFMO. The tumors that regrew were spindle cell carcinomas, an aggressive undifferentiated variant of SCC. At 1% DFMO in the drinking water, tumors also responded rapidly, but tumor regrowth did not occur. The majority of DFMO-treated SCCs were classified as complete responses, and in some cases, apparent tumor cures were achieved. The enzymatic activity of ODC, the target of DFMO, was substantially reduced after treatment with 1% DFMO and the high SCC polyamine levels, especially putrescine, were also significantly lowered. Based on the results of BrdUrd labeling and TUNEL assays, the effect of DFMO on SCC growth was accompanied by a significant reduction in tumor proliferation with no increase in the apoptotic index. These results demonstrate that SCCs, at least in the mouse, are particularly sensitive to polyamine-based therapy.
|How to cite this article:|
Chen Y, Hu J, Boorman D, Klein-Szanto A, O'Brien TG. Therapy of murine squamous cell carcinomas with 2-difluoromethylornithine. J Carcinog 2004;3:10
| Introduction|| |
Targeted overexpression of ornithine decarboxylase (ODC) to mouse epidermal keratinocytes with a bovine keratin 6 (K6) promoter/regulatory region greatly increases susceptibility to skin tumor development . In fact, in the K6/ODC transgenic model, treatment with exogenous tumor promoters such as 12-0 tetradecanoylphorbol-13-acetate (TPA) is dispensable: a maximal tumor response occurs after a single initiating application of a carcinogen such as 7, 12-dimethlybenz(a)anthracene (DMBA). The increased activity of the ODC transgene in this model is clearly necessary for the enhanced susceptibility phenotype as exposure of initiated mice to the ODC inhibitor 2 - difluoromethylornithine (DFMO) completely prevents papilloma development . Additionally, expression of the transgene is also important for maintenance of papilloma growth as DFMO treatment of papilloma-bearing mice causes complete tumor regression .
The predominant tumor type induced in most mouse models of skin cancer, especially those involving initiation/promotion protocols, is benign squamous papilloma. Squamous cell carcinomas, if they develop at all, are a small fraction of total tumors and appear with a long latency (6-12 months). Recently, a PKC-ε transgenic mouse (on an FVB background) has been reported to develop predominantly squamous cell carcinomas after a DMBA/TPA protocol . Similarly, when the K6/ODC transgene was placed on a congenic FVB background, SCCs developed rapidly and in high multiplicity after DMBA exposure . Finally, a bi-transgenic K6/ODC; TG.AC model [on a (FVB × B6)F1 background] develop SCCs spontaneously due to the combined effects of ODC overexpression and the v-Ha-ras gene present in the TG.AC line . The common feature of all these recently developed transgenic mouse models of SCC is the FVB genetic background, indicating the presence of SCC-predisposing genes in this strain. In the FVB/N strain itself, Hennings et al reported a higher percentage of papillomas progressed to SCCs in this strain than is typical of other susceptible strains .
Because of the short latency and high multiplicity of SCCs in the K6/ODC (FVB) model, it could serve as a useful preclinical model of human SCC. Specifically, existing or novel therapeutic approaches against SCC could be evaluated in this model. Because of the effectiveness of DFMO as a therapy for squamous papillomas, we have evaluated this drug as single-agent therapy for SCC. Our results demonstrate that murine SCCs are remarkably sensitive to DFMO treatment, suggesting that polyamine-based therapy may be a novel approach to the treatment of human SCC.
| Methods|| |
Animals and treatments
The K6/ODC model on the FVB/N strain background instead of the original C57BL/6J background was used in all experiments. To induce SCCs, newborn (1 day old) pups were treated with a single dose of 200 nmol of 7,12-dimethylbenz[a]anthracene (DMBA) dissolved in 50 μl acetone applied to the dorsal skin. Treatment area was approximately 40-50 mm 2 . SCCs typically developed on the treated area beginning 5 weeks later. SCC bearing mice with tumor volumes in the range 250-1500 mm 3 were randomized to experimental groups between 8 and 16 weeks of age.
Groups of tumor-bearing mice (n = 5-18) were treated with DFMO dissolved at 1 or 2% in the drinking water. DFMO solutions were changed every 4 days or less. Animals were observed daily for signs of distress due to tumor burden and/or DFMO treatment. Tumor volume was calculated according to the equation
where l = length (longest dimension) and w = width.
Tumor harvest, ODC and polyamine measurements
SCC-bearing mice were rapidly euthanized, SCCs excised, and a piece or pieces placed in Fekete's fixative for histopathologic diagnosis and the remaining tumor was placed immediately on dry ice and transferred to -80°C for subsequent biochemical determinations. Tumor-bearing mice used for these analyses were randomized by tumor size for placement into control or DFMO-treated groups. ODC activity and polyamine levels were measured in buffer extracts and 0.2 N PCA extracts of tissue, respectively . Buffer extracts for ODC determination from DFMO-treated mice were dialyzed overnight vs 1000-fold excess of buffer to remove free DFMO. One unit of ODC activity corresponds to 1 nmol of C0 2 liberated/h. ODC specific activity is expressed as units/mg protein. Polyamine levels are expressed as nmol/mg DNA.
Measurement of apoptosis and cell proliferation in SCCs
Tumor-bearing mice were injected i.p. with BrdUrd (100 μg/g body weight) 1 hour before sacrifice. Mice were randomized into control and DFMO-treatment groups based on tumor size. Pieces of tumor were fixed overnight in Fekete's solution and processed for paraffin embedding. Assessment of apoptotic and cell proliferation indices was performed using a TUNEL-based assay and detection of incorporation of BrdUrd into nuclei, respectively, as previously described . Differences in these parameters between control and treatment groups were assessed by ANOVA using StatView® (SAS Institute).
| Results|| |
Efficient induction of cutaneous SCCs in K6/ODC (FVB) mice
We have previously reported the propensity of K6/ODC mice (founder line 55/2 m) on an FVB background to develop SCCs rapidly after a single dose of 200 nmol DMBA . Due to breeding problems with 55/2 m founder line, mice from a second founder line 39/1m were treated with a single dose of DMBA (either 50 or 200 nmol) to determine if SCCs are also induced in this line. [The papilloma response of these two lines on a C57BL/6J background is identical . The results [Figure 1] confirm the high sensitivity of K6/ODC (FVB) mice from this founder line to SCC induction: maximal SCC multiplicities of 2.1 ± 0.3 and 4.3 ± 0.6 were observed in mice treated with 50 and 200 nmol DMBA, respectively. For the studies described, mice from both founder lines were used. The latent period for SCC appearance in this model is remarkably short, 5-6 weeks, compared to other models (typically 6 months or longer). As previously reported , the majority of tumors that developed were SCCs, not benign papillomas typically found in most other models.
Effect of DFMO on growth of murine SCCs
Based on the therapeutic effect of DFMO on papillomas in both C57BL/6(B6) and K6/ODC(B6) mice , SCC-bearing K6/ODC(FVB) mice were administered DFMO in the drinking water at a concentration of 2% (w/v). The SCCs exhibited a biphasic response to DFMO: there was a pronounced volume reduction of each tumor over the first two weeks of treatment, followed in five of six cases by a rapid regrowth of the tumor in the continued presence of DFMO [Figure 2]. When the tumors that regrew were examined histologically, all were diagnosed either as spindle cell carcinomas or mixed squamous cell and spindle cell carcinoma. Immunostaining with an anti-keratin antibody confirmed the diagnosis as spindle cell carcinomas (as opposed to undifferentiated sarcomas). Spindle cell carcinomas are an anaplastic, highly aggressive, variant of SCC in the mouse . A typical squamous cell carcinoma and spindle cell carcinoma are shown in [Figure 3]. The extremely rapid regrowth of the spindle cell carcinomas in the continued presence of DFMO raised the question whether ODC activities and polyamine levels were affected in these tumors. Prior to treatment, SCCs express abundant levels of ODC and polyamine levels, especially putrescine, are extraordinarily high [Table 1]. In contrast, the spindle cell carcinomas express, in general, low levels of ODC and greatly reduced polyamine levels. The one spindle cell carcinoma with moderately elevated ODC and polyamine levels was actually a mixed tumor composed of both squamous cell carcinoma and spindle cell carcinoma components, suggesting the former contributes most of the measured ODC activity and polyamines. These results indicate that excessively elevated ODC and polyamines are not required for growth of spindle cell carcinomas.
A second, larger, study was conducted to determine the response of SCCs to 1% DFMO. Compared to control SCC-bearing mice, after a one-week lag period, tumor-bearing mice administered 1% DFMO exhibited a rapid reduction in tumor volume [Figure 4]. The response of individual tumors to 1% DFMO is shown in [Table 2] of the 16 SCCs, 15 responded with at least an 80% volume reduction while 1 tumor was non-responsive (17A). Of 8 tumors evaluable after 10 weeks of observation, (2 mice with 8 SCCs died unexpectedly after 6-7 weeks on DFMO), five tumors (62.5%) exhibited complete responses and 1 responded with a >95% reduction in tumor volume. For 2 of the tumors that responded completely, (14A and 20A) a follow-up period of 5-6 weeks indicated no tumor regrowth after cessation of DFMO therapy. Thus, in contrast to the results with 2% DFMO [Figure 2], we observed no outgrowth of highly aggressive spindle cell carcinomas after treatment with 1% DFMO, and in fact some SCCs appear to have been cured by this therapy. However, studies involving a longer follow-up period than 5-6 weeks are required to reach definite conclusions regarding tumor cures after DFMO therapy.
Effect of DFMO on ODC activity and polyamine levels
In order to determine the effect of DFMO on its only known target, we measured ODC activities in tumors following 1% DFMO treatment for 1-8 days. This period was chosen based on previous results in squamous papillomas . Control SCCs expressed very high levels of ODC, albeit with a substantial variability from tumor to tumor [Table 3]. DFMO treatment led to a rapid and substantial decrease in SCC ODC activity; as early as 24 hours after the start of DFMO therapy, the mean ODC activity was reduced by 91% [Table 3]. By 8 days after DFMO, ODC activity was reduced by greater than 96%. Despite very high levels of pretreatment ODC activity, DFMO administered p.o. was able to rapidly normalize enzyme levels to values typical of K6/ODC epidermis .
We also measured polyamine levels in the same tumors used for ODC analyses. As expected based on previous studies of benign tumors in this model , putrescine is the most abundant polyamine in untreated SCCs, presumably due to the high level of ODC expression compared to downstream enzymes in putrescine metabolism (S-adenosyl-L-methionine decarboxylase, spermidine synthase). After 1% DFMO treatment, SCC polyamine levels, especially putrescine, declined rapidly [Table 3]. As early as 24 hours after drug treatment, putrescine levels were reduced 71%. After 8 days of treatment, putrescine levels were reduced 88% from untreated SCC levels. Spermidine and spermine levels also declined by approximately 50% over the 8-day treatment period.
Effect of DFMO on tumor proliferation and apoptotic index
To investigate the mechanism of DFMO-induced SCC regression, we measured the proliferation index and fraction of cells undergoing apoptosis in untreated and 1% DFMO-treated tumor-bearing mice. Consistent with previous results with benign squamous papillomas , DFMO treatment did not cause an increase in the number of cells undergoing apoptosis in SCCs. [Table 4]. Instead, at 48 hours and later after treatment, a significant reduction in apoptotic cells was observed. These results indicate that an induction of a large number of apoptotic cells after DFMO treatment is not involved in the early response of SCCs to DFMO, although we can not rule out a role for apoptosis at later times following DFMO therapy.
In marked contrast to the apoptotic index, DFMO had a rapid effect on tumor proliferation [Table 5]. The percentage of BrdUrd-positive cells was decreased as early as 24 hours after DFMO therapy, reached a maximum at 48 hours (73% inhibition), and was significantly decreased through 8 days of treatment. As described earlier, polyamine levels, especially putrescine, are decreasing precipitously throughout this 8-day period. These results are consistent with our previous studies in squamous skin papillomas indicating a regulatory role for polyamines, and in particular putrescine, in neoplastic growth .
| Discussion|| |
On all inbred strain backgrounds examined to date, expression of the K6/ODC transgene increases susceptibility of skin to tumor development [1,4] and unpublished results]. On most strain backgrounds, the great majority of tumors induced in this model after a single low dose of a carcinogen such as DMBA are benign squamous papillomas. On the FVB/N background however, DMBA induces predominantly squamous cell carcinomas [Figure 1] and reference ). The predisposition to SCC development of K6/ODC (FVB) mice is consistent with the results of others using different models on an FVB strain background [3, 5, 6]. A unique feature of the K6/ODC(FVB) model is the very short latency of tumor development (5-6 weeks) and high tumor multiplicity [Figure 1]. These properties favor its utility as an autochthonous mouse model of SCC development, amenable to rapid preclinical testing of new therapeutic modalities.
Based on previous studies showing efficacy of the ODC inhibitor DFMO against squamous papillomas in K6/ODC B6 mice, we asked whether this drug would be effective against SCCs. The answer is clearly yes, although significant differences exist in outcomes depending on the dose of DFMO used. At a 2% dose level, all SCCs responded initially with a substantial volume reduction, but in the great majority of cases (83%) tumors rapidly regrew in the continuous presence of DFMO. Interestingly, these DFMO-resistant tumors were of a different histologic type (spindle cell carcinoma or mixed spindle cell/squamous cell carcinoma) and had markedly reduced ODC and polyamine levels. It appears that this high concentration of DFMO selects for a "new" tumor type that does not require high polyamine levels for growth. The mechanism responsible for this selection process is not known. However, since most DMBA-induced skin tumors in K6/ODC (and other) mice contain a mutant c-Ha-ras allele, a possible mechanism involves loss of the wild-type c-Ha-ras allele as suggested by others . This possibility is currently under investigation.
Lowering the dose of DFMO to 1% greatly improved the eventual therapeutic outcome: the early response of SCCs to this dose was similar to mice treated with 2% DFMO, but no spindle cell carcinomas emerged. It is presently not clear why reducing the DFMO dose from 2% to 1% eliminates the high rate of conversion of SCCs to spindle cell carcinomas. However, the absence of such a transition allowed us to evaluate the effect of long-term DFMO treatment on SCCs. In the 1% DFMO treatment group, we achieved a complete response rate of 62.5% (5/8) and a partial response of 12.5%. Of the complete responders, at least 2 tumors were apparently cured, based on the lack of tumor regrowth over a 5-6 week period after cessation of DFMO. To our knowledge, there are no published reports of curative therapy using DFMO in any preclinical tumor model. Looking forward to potential human trials in SCC patients it should be emphasized that oral dose levels of 1-2 % used in this study are roughly 10-20 times higher than has ever been administered to humans in early therapeutic trials . Ongoing studies are evaluating lower doses of DFMO (more relevant to tolerable human doses) to determine efficacy in this preclinical SCC model.
As opposed to human tumor xenografts [12-14] there have been relatively few studies of the efficacy of DFMO as a therapeutic agent against autochthonous rodent tumors. Zhang, et al, demonstrated that 3% DFMO in the drinking water retarded the growth of small colon tumors (probably adenomas) in azoxymethane-treated rats . These tumors eventually began to regrow in the presence of DFMO, reminiscent of the current results with 2% DFMO. Previous results from this laboratory demonstrated complete regression of benign squamous papillomas after 1% DFMO treatment in both C57BL/6J and K6/ODC. C57BL/6J mice . Finally, Lan, et al  reported nearly complete regression of keratoacanthomas (a form of SCC) after 1% DFMO in a model similar, in many respects, to ours (bitransgenic K6/ODC; TG.AC mice on a (B6 × FVB)F1 background); in this model spontaneous SCC development is driven by the combined effect of a v-Ha-ras oncogene and ODC overexpression. Taken together, our results and those of Lan, et al, indicated that autochthonous squamous tumors, both benign and malignant, appear to be particularly responsive to single agent therapy with DFMO. In a study relevant to human SCCs of the head and neck, DFMO at 1.5% inhibited both the growth of SCC-derived cell lines in vitro and SCC xenografts in athymic mice .
As expected, DFMO treatment rapidly inhibited the enzymatic activity of its only cellular target, ODC, and reduced polyamine levels. A reduction in these parameters was observed as early as 24 hours after DFMO administration in the drinking water. In contrast to normal tissues, putrescine accumulates to extraordinary levels in SCCs and is the most abundant polyamine in these tumors. We have speculated that putrescine, rather than spermidine and/or spermine, is the regulatory polyamine for modulating the neoplastic phenotype , but this question is difficult to answer in a complex in vivo model. DFMO over an 8-day period was able to reduce putrescine levels by 88%, with lesser reductions in spermidine and spermine levels. Over the same time period, the tumor proliferation index was reduced by 50%. If the rate of cell loss due to terminal differentiation remains the same during the course of DFMO therapy, tumor volume reduction could be explained simply by this effect of DFMO on tumor proliferation. In this model of SCC, DFMO did not cause an increase in apoptosis over the same period in which polyamine levels are decreasing rapidly, tumor cell proliferation is reduced, and tumor volume is shrinking. In contrast, the apoptotic index actually decreased after DFMO therapy. There are conflicting reports on the effect of DFMO on apoptosis in various in vivo models. In a rat model of esophageal squamous cell carcinoma driven by zinc deficiency, Fung et al  reported an induction (approximately 2.5 fold) of apoptosis after 1% DFMO treatment in the esophageal epithelium. Similar results have been reported in rat colonic adenomas  and human gastric carcinoma xenographs . In the bitransgenic K6/ODC; TG.AC model of SCC, very similar to the model used in our studies, Lan et al  found that 1% DFMO treatment increased the apoptotic index in both small and large squamous tumors in the same time period we have found a decrease in apoptotic index in SCCs [Table 4]. While the reason for these discordant results in two very similar models are not readily apparent, there are at least two significant differences between the models that might explain the results. The SCCs in the K6/ODC model were induced by DMBA, which causes a variety of single point mutations in the c-Ha-ras and c-Ki-ras genes . In the bitransgenic K6/ODC; TG.AC model, tumors developed spontaneously due to combined expression of a strong, doubly-mutated v-Ha-ras oncogene and the K6/ODC transgene. The second difference in the two models is genetic background: FVB for the K6/ODC model and (B6 × FVB)F1 for the bitransgenic model, raising the intriguing possibility of modifier alleles in the B6 strain capable of modifying the apoptotic response of SCCs to DFMO. In human actinic keratoses, premalignant squamous lesion of the skin, topical DFMO (10%) treatment causes lesion regression . This effect of DFMO occurred without change in the apoptotic index , consistent with our previous results in mouse squamous papillomas. Taken together, these results suggest that the apoptotic response of a tissue or tumor to DFMO may depend on the complex interplay of several factors, including tissue type, degree of malignancy, nature of the genetic alterations present, and possibly genetic background.
In summary, autochthonous mouse SCCs appear to be very susceptible to therapy with DFMO. However, at the highest dose tested (2%) the initial positive response of SCCs was followed by the emergence of a histologically different tumor, spindle cell carcinoma, which is resistant to DFMO. This selection for DFMO-resistant tumor growth did not occur at 1% dose level. While early (reviewed in ) and more recent [25,26] trials of DFMO against advanced cancers have been generally disappointing, there are no published reports of the use of DFMO against SCCs at any organ site. Upon further development, human SCCs should be evaluated as candidates for polyamine-based therapy using DFMO, either with or without standard chemotherapy regimens.
| Acknowledgments|| |
The authors thank Dr. Alexander Muller for helpful comments on the manuscript and Loretta Rossino for editorial assistance. This research was supported by grant CA 94107 (to TGO) from the National Institutes of Health, Public Health Service, Department of Health, and Human Services. We thank Ilex Oncology, Inc for generously supplying DFMO for these studies.
| References|| |
|1.||O'Brien TG, Megosh LC, Gilliard G, Peralta Soler A: Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res 1997, 57: 2630-2637. |
|2.||Peralta Soler A, Gilliard G, Megosh L, George K, O'Brien TG: Polyamines regulate expression of the neoplastic phenotype in mouse skin. Cancer Res 1998, 58: 1654-1659. |
|3.||Jansen AP, Verwiebe FG, Dreckschmidt NE, Wheeler DL, Oberley TD, Verma AK: Protein Kinase C-e Transgenic Mice: A Unique Model for Metastatic Squamous Cell Carcinoma. Cancer Res 2001, 61: 808-812. |
|4.||Megosh LC, Hu J, George K, O'Brien TG: Genetic control of polyamine-dependent susceptibility to skin tumorigenesis. Genomics 2002, 79: 505-512. |
|5.||Smith M.K., Trempus, C.S., Gilmour, S.K.: Co-operation between follicular ornithine decarboxylase and v-Ha-ras induces spontaneous papillomas and malignant conversion in transgenic skin. Carcinogenesis 1998, 19: 1409-1415. |
|6.||Hennings H., Glick, A.B., Lowry, D.T., Krsmanovic, L.S., Sly, L.M. and Yuspa, S.H.: FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 1993, 14: 2353-2358. |
|7.||Koza RA, Megosh LC, Palmieri M, O'Brien TG: Constitutively elevated levels of ornithine and polyamines in mouse epidermal papillomas. Carcinogenesis (Lond) 1991, 12: 1619-1625. |
|8.||Chen YL, Megosh L, Gilmour SK, Sawicki JA, O'Brien TG: K6/ODC transgenic mice as a sensitive model for identification of chemical carcinogens. Toxicol Lett 2000, 116: 27-35. |
|9.||Klein-Szanto AJ, Larcher F, Bonfil RD, Conti CJ: Multistage chemical carcinogenesis protocols produce spindle cell carcinomas of the mouse skin. Carcinogenesis 1989, 10: 2169-2172. |
|10.||Buchmann A, Ruggeri B, Klein-Szanto AJ, Balmain A: Progression of squamous carcinoma cells to spindle carcinomas of mouse skin is associated with an imbalance of H-ras alleles on chromosome 7. Cancer Res 1991, 51: 4097-4101. |
|11.||Schechter PJ, Barlow JLR, Sjoerdsma A: Clinical aspects of inhibition of ornithine decarboxylase with emphasis on therapeutic trials of Eflornithine (DFMO) in cancer and protozoan diseases. Inhibition of polymine metabolism biological significances and basis for new therapies (Edited by: McCann PP, Pegg AE and Sjoerdsma A). Orlando, Academic Press 1987, 345-363. |
|12.||Luk GD, Abeloff MD, Griffin CA, Baylin SB: Successful treatment with DL-a-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice. Cancer Res 1983, 43: 4239-4243. |
|13.||Shaw MW, Guinan PD, McKiel CF, Dubin A, Rubenstein M: Combination therapy using polyamine synthesis inhibitor alpha-difluoromethylornithine and adriamycin in treatment of rats carrying the Dunning R3327 MAT-LyLu prostatic adenocarcinoma. The Prostate 1987, 11: 87-93. |
|14.||Upp J.R., Jr., Beauchamp RD, Townsend C.M., Jr., Barranco SC, Singh P, Rajaraman S, James E, Thompson JC: Inhibition of human gastric adenocarcinoma xenograft growth in nude mice by a-difluoromethylornithine. Cancer Res 1988, 48: 3265-3269. |
|15.||Zhang S.Z., Luk, G.D. and Hamilton, S.R.: Alpha-difluoromethylornithine-induced inhibition of growth of autochthonous experimental colonic tumors produced by azoxymethane in male F344 rats. Cancer Res 1988, 48: 6498-6503. |
|16.||Lan Li, Trempus Carol, Gilmour Susan K.: Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice. Cancer Res 2000, 60: 5696-5703. |
|17.||Petereit DG, Harari PM, et al: Combining polyamine depletion and radiation therapy for rapidly dividing head and neck tumors: strategies for improving locoregional control. Int J Rad Oncol Biol Phys 1994, 28: 891-898. |
|18.||Fong LYY, Nguyen VT, Pegg AE, Maggee PN: a-Difluoromethylornithine induction of apoptosis: a mechanism which reverses pre-established cell proliferation and cancer initiation in esophageal carcinogenesis in zinc-deficient rats. Cancer Epidemiology, Biomarkers & Prevention 2001, 10: 191-199. |
|19.||Li H, Schut HAJ, Conran P, Kramer PM, Lubet RA, Steele VE, Hawk EE, Kelloff GJ, Pereira MA: Prevention by aspirin and its combination with a-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 1999, 20: 425-430. |
|20.||Takahashi Y, Mai M, Nishioka K: a-Difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibitiion of tumor growth and metastasis in a human gastric cancer mode. Int J Cancer 2000, 85: 243-247. |
|21.||Megosh L, Halpern M, Farkash E, O'Brien TG: Analysis of ras gene mutational spectra in epidermal papillomas from K6/ODC transgenic mice. Mol Carcinog 1998, 22: 145-149. |
|22.||Alberts DS, Dorr RT, Einspahr JG, Aickin M, Saboda K, Xu MJ, Peng YM, Goldman R, Foote JA, Warneke JA, Salasche S, Roe DJ, Bowden GT: Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol, Biomarkers Prev 2000, 9: 1281-1286. |
|23.||Einspahr JG, Nelson MA, Saboda K, Warneke JA, Bowden GT, Alberts DS: Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. Clin Cancer Res 2002, 8: 149-155. |
|24.||Meyskens FL, Gerner EW: Development of difluoromethylornithine (DFMO) as a chemopreventive agent. Clin Cancer Res 1999, 5: 945-951. |
|25.||O'Shaughnessy Joyce A., Demers Laurence M., Jones Stephen E., Arseneau James, Khandelwal Pankaj, George Timothy, Gersh Robert, Mauger David, Manni Andrea: a-Difluoromethylornithine as treatment for metastatic breast cancer patients. Clin Cancer Res 1999, 5: 3438-3444. |
|26.||Levin VA, Hess KR, Choncair A, Flynn PJ, Jacekle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Irtech S, Gleason MJ, Kim HW: Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylormithine-PCV versus PCV for anaplastic glcomas. Clin Cancer Res 2003, 9: 981-990. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]
|This article has been cited by|
||Polyamines and nonmelanoma skin cancer
| ||Gilmour, S.K. |
| ||Toxicology and Applied Pharmacology. 2007; 224(3): 249-256 |
||Polyamine functions and metabolism | [Métabolisme et fonctions des polyamines]
| ||De Bandt, J.-P., Moinard, C., Cynober, L. |
| ||Immuno-Analyse et Biologie Specialisee. 2006; 21(6): 333-341 |
||Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma
| ||Chen, Y., Weeks, R.S., Burns, M.R., Boorman, D.W., Klein-Szanto, A., OæBrien, T.G. |
| ||International Journal of Cancer. 2006; 118(9): 2344-2349 |
||Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma
| ||Yan Chen,Reitha S. Weeks,Mark R. Burns,David W. Boorman,Andres Klein-Szanto,Thomas G. OæBrien |
| ||International Journal of Cancer. 2006; 118(9): 2344 |
|[Pubmed] | [DOI]|
||Métabolisme et fonctions des polyamines
| ||J.-P. De Bandt,C. Moinard,L. Cynober |
| ||Immuno-analyse & Biologie Spécialisée. 2006; 21(6): 333 |
|[Pubmed] | [DOI]|
||Polyamines: Metabolism and implications in human diseases
| ||Moinard, C., Cynober, L., de Bandt, J.-P. |
| ||Clinical Nutrition. 2005; 24(2): 184-197 |